Search
Avutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigational[L53203] It has been under investigation in humans since at least 2012. … Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway.
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigationalHydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928.
Telcagepant
go.drugbank.com/drugs/DB12228InvestigationalIt is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine.
SCB-2019
go.drugbank.com/drugs/DB15805InvestigationalAs of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine. … SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19.
Famprofazone
go.drugbank.com/drugs/DB16702ExperimentalFamprofazone is a nonsteroidal anti-inflammatory agent found in combination products such as ‘Gewodin’ which is marketed in Taiwan.
Navitoclax
go.drugbank.com/drugs/DB12340InvestigationalNavitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer.
Paramethasone
go.drugbank.com/drugs/DB01384ExperimentalA glucocorticoid with the general properties of corticosteroids.
Caviar, unspecified
go.drugbank.com/drugs/DB14241ApprovedCaviar, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Isoaminile
go.drugbank.com/drugs/DB08944ApprovedWithdrawnIsoaminile, an antitussive drug with a structure similar to methadone, is also an anticholinergic with both antimuscarinic and antinicotinic properties.
Meropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalMeropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. … In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI).